Skip to content

What is siinfekl peptide? A Key Tool in Immunology

3 min read

First characterized as a key part of chicken ovalbumin, the siinfekl peptide is an 8-amino acid sequence that has become a powerful and widely used model antigen for stimulating CD8+ T-cell responses in immunological studies. It is an immunodominant epitope specifically recognized by the murine immune system and is foundational for understanding antigen processing and presentation.

Quick Summary

The SIINFEKL peptide is an immunodominant epitope from chicken ovalbumin, serving as a critical research tool for studying antigen presentation and T-cell activation in mice, with wide application in vaccine development and cancer immunotherapy research.

Key Points

  • Source: SIINFEKL is an 8-amino-acid peptide derived from chicken ovalbumin protein, specifically the OVA257-264 sequence.

  • Immune Epitope: It functions as an immunodominant epitope that binds with high affinity to the murine MHC class I molecule, H-2Kb.

  • Activates CD8+ T Cells: When presented on the surface of antigen-presenting cells, SIINFEKL potently stimulates CD8+ cytotoxic T lymphocytes in mouse models like C57BL/6 mice.

  • Research Tool: This peptide is a standard tool in immunology for studying antigen presentation, monitoring T-cell responses, and testing novel immunotherapeutic strategies.

  • Adjuvant Properties: Research has shown that SIINFEKL can self-assemble into a stable hydrogel with inherent immunoactive properties, which is a key consideration for its use in adjuvant testing.

  • Vaccine and Immunotherapy: It is widely used in preclinical research for developing and evaluating new peptide-based cancer vaccines and immune-modulating drugs.

In This Article

What is the SIINFEKL Peptide?

The SIINFEKL peptide is a short, eight-amino-acid long polypeptide with the sequence Ser-Ile-Ile-Asn-Phe-Glu-Lys-Leu. It is a critical research tool, particularly in immunology, derived from the chicken ovalbumin (OVA) protein, a main component of egg white. In immunology, an epitope is the part of an antigen recognized by the immune system, and SIINFEKL is a potent and well-studied epitope for research.

Mechanism of Action in the Immune System

The SIINFEKL peptide acts as a model antigen to stimulate a specific immune response through the major histocompatibility complex (MHC) class I pathway. This involves:

  • Intracellular Processing: Ovalbumin is broken down into peptide fragments within an antigen-presenting cell (APC).
  • MHC Class I Binding: The SIINFEKL fragment strongly binds to the murine MHC class I molecule, H-2Kb.
  • Surface Presentation: The APC presents the H-2Kb-SIINFEKL complex on its surface.
  • T-cell Activation: This leads to the activation of SIINFEKL-specific CD8+ cytotoxic T lymphocytes (CTLs).

Applications in Immunological Research

The predictable immune response to SIINFEKL makes it an invaluable tool in preclinical and immunological research, especially with mouse models like the OT-I transgenic mouse.

Cancer Immunotherapy

  • Vaccine Evaluation: Used to assess cancer vaccine candidates by monitoring the T-cell response to SIINFEKL.
  • Immune Checkpoint Inhibitors: Helps screen the effectiveness of these inhibitors by observing their impact on antigen-specific T-cell activity.
  • Antigen Delivery: Incorporated into delivery systems to target cancer cells and trigger an immune response.

Vaccine Development

  • Adjuvant Testing: Used to evaluate new vaccine adjuvants, though its newly discovered ability to form a hydrogel may act as an independent immune booster.
  • Peptide-Based Vaccines: Serves as a model for designing such vaccines to induce strong cytotoxic T-cell responses.

General Immunological Studies

  • Antigen Presentation Studies: A standard for MHC class I antigen presentation assays.
  • T-cell Assays: Used in assays like ELISPOT and flow cytometry to quantify antigen-specific CD8+ T-cell responses.

Comparison of SIINFEKL Peptide and Ovalbumin Protein

Feature SIINFEKL Peptide (OVA257-264) Ovalbumin Protein (Full-length)
Source 8-amino acid fragment of Ovalbumin Entire 385-amino-acid protein
Immune Presentation Directly loaded onto MHC Class I molecules by APCs Must be processed by APCs before its epitopes can be presented
Immune Response Primarily stimulates a strong and specific CD8+ T-cell response Elicits a broader immune response, including both CD4+ and CD8+ T-cell activation
Efficiency Highly efficient at stimulating H-2Kb-restricted CD8+ T-cell responses in mice Less efficient for inducing a specific CD8+ T-cell response compared to the peptide alone
Adjuvant Potential Has shown the ability to self-assemble into a hydrogel with adjuvant-like properties Requires other adjuvants to enhance immunogenicity in vaccine models

The Discovery of Self-Assembly

Recent research highlighted the unexpected property of the SIINFEKL peptide to self-assemble into nanofibres forming a stable hydrogel. This process is stabilized by beta-sheet stacking, with hydrophobic isoleucine residues being crucial. This finding is significant for adjuvant testing, as the peptide itself may possess inherent immune-stimulating effects.

Conclusion

The SIINFEKL peptide, a fragment of chicken ovalbumin, is a fundamental tool in immunological and preclinical research. Its role as a precise model antigen has advanced our understanding of T-cell biology, antigen presentation, and the development of immunotherapies and vaccines. While its research value is significant, its newly discovered self-assembly into a hydrogel warrants careful consideration in certain applications like adjuvant testing. Ultimately, SIINFEKL remains a powerful tool for exploring the adaptive immune system. Ovalbumin Epitope SIINFEKL Self-Assembles into a Supramolecular Hydrogel

Frequently Asked Questions

The SIINFEKL peptide consists of eight amino acids in the sequence: Serine-Isoleucine-Isoleucine-Asparagine-Phenylalanine-Glutamic acid-Lysine-Leucine, often denoted as Ser-Ile-Ile-Asn-Phe-Glu-Lys-Leu.

This peptide is an epitope derived from the ovalbumin (OVA) protein, which is found in chicken egg whites.

It functions as a model antigen by binding to the MHC class I molecule H-2Kb in mice. When presented on the cell surface, it activates antigen-specific CD8+ T cells.

The peptide has a strong binding affinity for the H-2Kb MHC molecule, which is specific to C57BL/6 mice. This makes it a standardized tool for studying T-cell responses in a controlled and well-understood animal model.

No, the SIINFEKL peptide is not used as a therapeutic drug in humans. It is an established research tool used in preclinical studies to understand immune mechanisms and evaluate potential drug candidates.

The discovery that SIINFEKL can self-assemble into a hydrogel has important implications for research. The hydrogel itself can act as an adjuvant and influence the immune response, which needs to be considered when using the peptide for testing other adjuvants.

Yes, SIINFEKL is extensively used in preclinical cancer immunotherapy research. It helps scientists evaluate the effectiveness of vaccine candidates, immune checkpoint inhibitors, and targeted antigen delivery strategies for stimulating anti-tumor immune responses.

As a research chemical, safety and side effects are primarily a concern within the specific experimental context. In mice, the dosage and use of adjuvants can influence the immune response. It is not a human therapeutic, so human-relevant side effects are not applicable.

References

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8

Medical Disclaimer

This content is for informational purposes only and should not replace professional medical advice.